Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.
P/B ratio for Oramed Pharmaceuticals Inc. (ORMP)
P/B ratio as of 2022: 3.09
According to Oramed Pharmaceuticals Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 3.09. At the end of 2021 the company had a P/B ratio of 4.84.
P/B ratio history for Oramed Pharmaceuticals Inc. from 2003 to 2022
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2022 | 3.09 |
| 2021 | 4.84 |
| 2020 | 2.18 |
| 2019 | 2.99 |
| 2018 | 2.37 |
| 2017 | 5.98 |
| 2016 | 3.48 |
| 2015 | 2.45 |
| 2014 | 4.51 |
| 2013 | 6.46 |
| 2012 | 5.98 |
| 2011 | 5.06 |
| 2010 | 26.96 |
| 2009 | 9.49 |
| 2008 | 7.62 |
| 2007 | 36.28 |
| 2006 | -71.01 |
| 2005 | -412.33 |
| 2004 | -92.36 |
| 2003 | -3480.00 |